Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Contrera

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Regulatory Toxicology and Pharmacology : RTP|August 24, 2013
Validation of Toxtree and SciQSAR in silico predictive software using a publicly available benchmark mutagenicity database and their applicability for the qualification of impurities in pharmaceuticalsJoseph F Contrera
Regulatory Toxicology and Pharmacology : RTP|October 12, 2010
Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impuritiesJoseph F Contrera
Expert Opinion on Drug Metabolism & Toxicology|February 3, 2007
In silico approaches to explore toxicity end points: issues and concerns for estimating human health effectsEdwin J Matthews, Joseph F Contrera
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 30, 2006
Genetic toxicity assessment: employing the best science for human safety evaluation. Part I: Early screening for potential human mutagensDavid Jacobson-Kram, Joseph F Contrera
Regulatory Toxicology and Pharmacology : RTP|November 19, 2003
Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indicesJoseph F Contrera, Edwin J Matthews, R Daniel Benz
Current Drug Discovery Technologies|February 14, 2006
QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptorsJoseph F Contrera, Philip Maclaughlin, Lowell H Hall, et al.
Regulatory Toxicology and Pharmacology : RTP|January 9, 2007
A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR databaseEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Toxicology and Applied Pharmacology|May 8, 2007
Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modelingLuis G Valerio, Kirk B Arvidson, Ronald F Chanderbhan, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2004
Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily doseJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Regulatory Toxicology and Pharmacology : RTP|October 26, 2005
In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR softwareJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Regulatory Toxicology and Pharmacology : RTP|August 24, 2013
Validation of Toxtree and SciQSAR in silico predictive software using a publicly available benchmark mutagenicity database and their applicability for the qualification of impurities in pharmaceuticalsJoseph F Contrera
Regulatory Toxicology and Pharmacology : RTP|October 12, 2010
Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impuritiesJoseph F Contrera
Expert Opinion on Drug Metabolism & Toxicology|February 3, 2007
In silico approaches to explore toxicity end points: issues and concerns for estimating human health effectsEdwin J Matthews, Joseph F Contrera
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 30, 2006
Genetic toxicity assessment: employing the best science for human safety evaluation. Part I: Early screening for potential human mutagensDavid Jacobson-Kram, Joseph F Contrera
Regulatory Toxicology and Pharmacology : RTP|November 19, 2003
Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indicesJoseph F Contrera, Edwin J Matthews, R Daniel Benz
Current Drug Discovery Technologies|February 14, 2006
QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptorsJoseph F Contrera, Philip Maclaughlin, Lowell H Hall, et al.
Regulatory Toxicology and Pharmacology : RTP|January 9, 2007
A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR databaseEdwin J Matthews, Naomi L Kruhlak, R Daniel Benz, et al.
Toxicology and Applied Pharmacology|May 8, 2007
Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modelingLuis G Valerio, Kirk B Arvidson, Ronald F Chanderbhan, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2004
Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily doseJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Regulatory Toxicology and Pharmacology : RTP|October 26, 2005
In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR softwareJoseph F Contrera, Edwin J Matthews, Naomi L Kruhlak, et al.
Pageof 3